Suggestions
Michael Milone
Associate Professor at University of Pennsylvania School of Medicine
Michael Milone is a co-founder and co-chair of the Scientific Advisory Board at Verismo Therapeutics, a company pioneering CAR T-cell therapy for the treatment of solid tumors.13 He is also an Associate Professor of Pathology and Laboratory Medicine at the University of Pennsylvania.6
Dr. Milone's background is impressive:
Education and Expertise
- He holds an M.D. in Medicine & Immunology and a Ph.D. in Immunology.4
- He has over 25 years of experience in cell and gene therapy as a physician-scientist.5
Contributions to CAR T-cell Therapy
Dr. Milone is one of the inventors of Kymriah™, the first FDA-approved CAR T-cell therapy.1 Building on this groundbreaking work, he co-founded Verismo Therapeutics to develop next-generation CAR T-cell therapies, specifically:
- The KIR-CAR platform, which aims to overcome limitations of first-generation CAR T therapies.1
- SynKIR™, a novel chimeric antigen receptor design based on killer immunoglobulin-like receptors (KIRs).3
Recent Developments
In 2024, Verismo Therapeutics received FDA clearance for a Phase I trial of its CAR-T therapy, SynKIR-310, targeting relapsed or refractory B-cell non-Hodgkin lymphomas.2 This represents a significant milestone in Dr. Milone's ongoing work to advance cell therapies for cancer treatment.
Dr. Milone's LinkedIn username is michael-milone-5a251736, as provided in the query.
